Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Like a candle in the wind, support for HIV responses risks burning out long before the epidemic ever will . . . On one hand, the […]
Global TB response advocates express continued concern about drug’s price First, a word about the significance of bedaquiline. The first new antituberculosis drug to be developed […]
As strategies to prevent HIV and unintended pregnancies evolve, concepts of “multi-purpose technologies” raise a familiar question . . .
What do women want? While two trials test vaginal rings to fight HIV, market research highlights respondents’ interests in different options It’s a question that gained […]
In November 2009, with a Congress contemplating a foreign aid overhaul, the news that a physician had just been named to take the long-vacant helm at […]